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Tre-2, BUB2, CDC16, 1 domain family member 4 (TBC1D4) (AS160) is
a Rab-GTPase activating protein implicated in insulin-stimulated glu-
cose transporter 4 (GLUT4) translocation in adipocytes and myotubes.
To determine whether loss-of-function mutations in TBC1D4 might
impair GLUT4 translocation and cause insulin resistance in humans,
we screened the coding regions of this gene in 156 severely insulin-
resistant patients. A female presenting at age 11 years with acan-
thosis nigricans and extreme postprandial hyperinsulinemia was
heterozygous for a premature stop mutation (R363X) in TBC1D4.
After demonstrating reduced expression of wild-type TBC1D4 protein
and expression of the truncated protein in lymphocytes from the
proband, we further characterized the biological effects of the trun-
cated protein in 3T3L1 adipocytes. Prematurely truncated TBC1D4
protein tended to increase basal cell membrane GLUT4 levels (P 
0.053) and significantly reduced insulin-stimulated GLUT4 cell mem-
brane translocation (P < 0.05). When coexpressed with wild-type
TBC1D4, the truncated protein dimerized with full-length TBC1D4,
suggesting that the heterozygous truncated variant might interfere
with its wild-type counterpart in a dominant negative fashion. Two
overweight family members with the mutation also manifested
normal fasting glucose and insulin levels but disproportionately
elevated insulin levels following an oral glucose challenge. This family
provides unique genetic evidence of TBC1D4 involvement in human
insulin action.
glucose transport  insulin resistance  AS160
B lood glucose levels are very precisely regulated in healthypeople despite enormous variation in the timing and mag-
nitude of carbohydrate ingestion. Postingestive insulin-
stimulated glucose uptake into skeletal muscle and adipose
tissue is an essential element of this tight metabolic regulation.
Glucose transporter 4 (GLUT4) selectively mediates insulin-
stimulated glucose transport into myotubes and adipocytes. The
importance of this metabolic step in vivo was demonstrated by
generating muscle and adipose tissue-specific GLUT4 knockout
mice, both of which are insulin resistant (1). Human physiolog-
ical studies suggest that defects in insulin-stimulated glucose
transport in muscle constitute the earliest abnormality in insulin-
resistant people (2). GLUT4 is the main insulin-responsive
hexose transporter. Insulin rapidly increases the amount of
GLUT4 in the plasmamembrane by causing specializedGLUT4-
containing vesicles to move from an intracellular location to the
plasmamembrane where the vesicles dock and then fuse with the
plasma membrane (3). This process is referred to as GLUT4
translocation. Whilst impaired GLUT4 translocation appears to
be common to many different insulin resistance-inducing met-
abolic insults (4), precisely how insulin triggers GLUT4 vesicle
movement and subsequent membrane fusion remains incom-
pletely understood. AKT2 is clearly activated in response to
insulin and triggers GLUT4 membrane translocation (5), but
until recently the link between proximal insulin signaling steps
[insulin receptor substrate (IRS)–phosphatidylinositol 3 kinase
(PI3K)–protein kinase B (AKT)] and GLUT4 translocation was
unknown. Tre-2, BUB2, CDC16, 1 domain family member 4
(TBC1D4) is a 160-kDaAKT substrate with aGTPase-activating
protein (GAP) domain and several AKT phosphorylation sites
(6, 7). Insulin-induced activation of AKT2 leads to phosphory-
lation of these sites. Considerable evidence indicates that phos-
phorylation of TBC1D4 suppresses its GAP activity, thereby
promoting elevation of the GTP-bound form of selected Rabs
and GLUT4 translocation (7–9) (Fig. 1). In the basal state,
TBC1D4 appears to maintain these Rabs in their GDP form and
so prevents GLUT4 translocation. TBC1D4 knockdown in
3T3L1 adipocytes increases basal cell membrane GLUT4 levels,
indicating that TBC1D4 Rab-GTPase activity is required for full
intracellular retention of GLUT4 storage vesicles (8, 9). Knock-
down of TBC1D4 also inhibits insulin-stimulated GLUT4 trans-
location by about 25% by a currently unknown mechanism (8).
Although rare, monogenic syndromes of severe insulin resis-
tance/type 2 diabetes can provide unique insight into the func-
tion of the affected gene/protein in humans as well as offering
clues to understanding more common polygenic disease (10). To
determine whether missense/nonsense mutations within
TBC1D4might alter glucose transport and predispose carriers to
insulin resistance, we screened all of the coding regions of
TBC1D4 in a cohort of 156 severely insulin-resistant patients.
Patients were selected for the study if they had acanthosis
nigricans, a cutaneous manifestation of extreme hyperinsulin-
aemia, and/or a fasting insulin level of greater than 150 pmol/L,
or if already diabetic at the time of referral, if they required more
than 200 units of insulin daily.
Results
Identification of a Premature StopMutation in TBC1D4.We identified
a heterozygous substitution of thymine for cytosine at nucleotide
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position 1,087 in exon 3, resulting in the substitution of a
premature stop codon (TGA) for arginine (CGA) at codon 363
(Fig. 2A) in a female patient with acanthosis nigricans. The
mutation is predicted to truncate the protein at amino acid 363
(R363X), resulting in loss of the proposed GAP domain and
several AKT phosphorylation sites (Fig. 2B) (6, 7). It was absent
in 200 ethnically matched control alleles. The proband was also
screened for mutations in other genes previously implicated in
GLUT4 translocation. No mutations were identified in SLC2A4
(solute carrier family 2 member 4/GLUT4), TBC1D1, VAMP2
(vesicle-associated membrane protein 2), STX4 (synatxin4),
SNAP23 (synaptosome-associated 23-kDa protein), RAB10, and
LNPEP [leucyl/cystinyl aminopeptidase/insulin-regulated ami-
nopeptidase (IRAP)].
As TBC1D4 is detectable in lymphocytes and the proband was
unwilling to have a muscle or fat biopsy, we documented reduced
expression of full-length TBC1D4 protein using both a C-
terminal and an N-terminal TBC1D4 antibody in lysates from
her Epstein Barr virus transformed lymphocytes (EBVLs) (Fig.
2C). We then confirmed that the truncated TBC1D4 protein was
expressed in the EBVLs by immunoprecipitating and then
immunoblotting with an antibody raised against the N terminus
of TBC1D4 (Fig. 2D).
Cellular Characterization of the R363X TBC1D4 Truncation Mutant.
When overexpressed in 3T3L1 adipocytes by 10-fold over
endogenous TBC1D4 (Fig. 3A), mutant TBC1D4 (R363X)
increased GLUT4 at the cell surface in the basal state by 31%
and inhibited the amount of GLUT4 at the plasma membrane in
the insulin-stimulated state by 12%, relative to the wild-type
TBC1D4 (Fig. 3B). The relatively modest effect of this prema-
ture stop mutant is probably accounted for by substantial
readthrough of the premature stop mutation; the signal from the
Flag-tagged readthrough product was about 4 times as strong as
that of the Flag-tagged truncated version (Fig. 3A). To more
effectively assay the impact of the truncated protein, we also
generated a vector that terminates the protein at position R363
(363Tr). Overexpression of this truncated protein (363Tr) by
Fig. 1. Schematic illustration of insulin-stimulated GLUT4 translocation. Bind-
ing of insulin (black circle) to its tetrameric receptor (2 - and 2 -subunits) leads
totyrosinephosphorylation(P)of insulin receptor substrate (IRS)proteinsandthe
recruitment of phosphatidylinositol 3 kinase (PI 3-kinase), which catalyzes the
conversion of PI(4,5)P2 to PI(3,4,5)P3. PI(3,4,5)P3 generation results in the phos-
phorylation of AKT2 (protein kinase B, beta) by 3-phosphoinositide-dependent
protein kinase 1 (PDK1) and transducer of regulated cAMP response element-
binding protein 2 (TORC2), causing its activation. AKT2 phosphorylates TBC1D4
(AS160) suppressing its GAP activity and resulting in active GTP-bound Rab
proteins that promote glucose transporter 4 (GLUT4) vesicle translocation.
PI(4,5)P2, phosphotidylinositol 4,5 bisphosphate; PI(3,4,5)P3, phosphotidylinosi-
tol 3,4,5 trisphosphate; GEF, guanine exchange factor; GTP, guanosine triphos-
phate; GDP, guanosine diphosphate; TBC1D4, Tre-2, BUB2, CDC16, 1 domain
family member 4 (also known as AS160, AKT substrate of 160 kDa.
Fig. 2. Identification of the R363X TBC1D4 mutation. (A) Wild-type TBC1D4 and R363X TBC1D4 mutant sequence traces. The heterozygous substitution of thymine
for cytosine results in the substitution of a stop codon for arginine (R) at amino acid 363. (B) Schematic representation of TBC1D4 showing the position of the R363X
premature stop mutation, phosphotyrosine binding domains (PTB, solid black regions), AKT phosphorylation sites (*), and RAB GTPase activating protein (GAP) domain
of TBC1D4 (checked region). (C) TBC1D4 expression levels (160 kDa) as determined by immunoblot analysis with both a C-terminal and N-terminal TBC1D4 antibody
in EBVL lysates from the proband (R363X) compared with protein expression in cells from one healthy control (control) and one severely insulin-resistant subject with
a loss-of-function mutation in the INSR gene (INSR). he lysates were reprobed with an antibody raised against the P85 subunit of PI3K to confirm equal loading. (D)
Expression of the truncated TBC1D4 protein in EBVL lysates from the proband confirmed by immunoprecipitation (IP) and subsequent immunoblotting with an
N-terminal TBC1D4 antibody. The unexpectedly large size of the truncated protein (about 80 kDa) is the result of the slower mobility of the nonreduced form (see Fig. S1).
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30-fold over the endogenous TBC1D4 increased cell surface
GLUT4 in the basal state by 38% and reduced insulin-stimulated
cell surface GLUT4 by 36%, relative to the wild-type TBC1D4
(Fig. 3B). Presentation of the data in Fig. 3B as the ratio of
GLUT4 at the cell surface in the insulin-stimulated state to that
in the basal state shows that both the mutant and 363Tr TBC1D4
proteins significantly reduce the fold increase in cell surface
GLUT4 (Fig. 3C). When coexpressed with wild-type TBC1D4,
the truncated protein binds to full-length TBC1D4, providing a
plausible mechanism whereby the heterozygous truncated vari-
ant could potentially interfere with its wild-type counterpart in
a dominant negative fashion (Fig. 3D).
Clinical Phenotyping and Family Cosegregation Studies.The proband
presented at the age of 11 with nuchal, groin, and axillary
acanthosis nigricans. At birth she weighed 2.4 kg [-0.8 BMI SDS
(body mass index standard deviation score)]. She remained slim
during early childhood but from the age of 6 years, her weight
increased and at the time of presentation her BMI SDSwas2.7.
Physical examination was otherwise normal. Her fasting glucose
and insulin levels fell within age-, gender-, and BMI-matched
ranges, but following an oral glucose challenge, she displayed
dramatic hyperinsulinemia (Table 1 and Fig. 4A). After puberty
and a period of weight loss (age 23 years; BMI SDS 1.4), her
acanthosis nigricans resolved. Although her glucose tolerance
had now normalized, she was still overweight and again displayed
an elevated peak-to-fasting insulin ratio of 14 (supporting in-
formation (SI) Table S1).
The heterozygous R363X mutation was present in the pro-
band’s half sister (Iii), mother (IIii), grandmother (IIIi), and a
maternal aunt (IIi) (Fig. 4B). Like the proband, her half sister
presented with weight gain (BMI SDS 3.5) and acanthosis
nigricans at the age of 9. She elected not to have blood sampling
but did provide a buccal swab for genotyping. Her mother, a
41-year-old woman, was obese (BMI SDS 3.1) but had no
acanthosis nigricans. Following an oral glucose load she too
manifested a disproportionate rise in insulin, reflected by an
elevated peak-to-fasting insulin ratio of 15 (Table 1). On repeat
testing, a year later, an elevated peak-to-fasting insulin ratio was
again found (Table S1). When first tested, the proband’s affected
aunt (Fig. 4B, IIi), an overweight 44-year-old woman (BMI 27
kg/m2), displayed a similarly elevated peak-to-fasting insulin
ratio of 17. Following diet-induced weight loss (4.5 kg), her BMI
fell to 24 kg/m2, and her peak-to-fasting insulin ratio normalized
to 7 (Table S1). The only unaffected member tested (IIiii), an
obese 38-year-old woman (BMI 37 kg/m2), manifested normal
glucose tolerance and a normal peak-to-fasting insulin ratio of 7
(Fig. 4B and Table S1). The proband’s grandmother (Fig. 4B,
IIIi) also carried the mutation. She had a peak-to-fasting insulin
ratio of 4, but at the time of testing she had an elevated fasting
glucose and impaired glucose intolerance, indicative of signifi-
cant -cell dysfunction (11). Since the peak-to-fasting insulin
ratio is dependent on the secretory capacity of the -cells, her
peak-to-fasting insulin ratios are difficult to interpret.
Discussion
Both insulin resistance and -cell failure are believed to result
from complex biochemical and gene–environment interactions.
Whereas considerable progress has already been made in un-
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Fig. 3. Cellular analysis of GLUT4 translocation. (A) In vitro expression levels
of TBC1D4 protein in 3T3L1 adipocytes (full-length TBC1D4 at 160 kDa and
truncated protein at 52 kDa) transfected with empty P3XFLAG CMV10 vector
(vector), wild-type TBC1D4 vector (WT), R363X vector (R363X), or the artifi-
cially generated 363 truncated protein (363Tr) vector as determined by im-
munoblotting with anti-Flag. We have also immunoblotted these samples
with an antibody against a conserved peptide in mouse and human TBC1D4.
Since the ectopic human TBC1D4 has a slightly lower mobility than the
endogenous mouse TBC1D4, it was possible to estimate the relative amounts
of each; the ectopic wild-type and R363X full length TBC1D4 were 10-fold
more abundant than the endogenous TBC1D4 (data not shown). Also then by
comparison of the anti-Flag signals of full-length R363X and 363Tr, we esti-
mate that the 363Tr was overexpressed by about 30-fold in the transfected
cells, relative to endogenous TBC1D4. (B) Cell surface GLUT4 levels, normal-
ized to a value of 1.0 for the vector control in the insulin-stimulated state.
Values are expressed as means SE for 4–6 independent measurements of the
Cy3/GFP ratio in cells with and without 30-min treatment with 160 nM of
insulin. (C) Data from Fig. 2B expressed as the ratio of cell surface GLUT4 in the
insulin-stimulatd state to that in the basal state. (D) Immunoblots (IB) showing
coimmunoprecipitation (IP) of T7-tagged TBC1D4 from basal (B) and insulin-
stimulated (I) 293 cells with Flag-tagged 363Tr or full-length TBC1D4. To
control for nonspecific immunoprecipitation, lysates were also immunoblot-
ted after immunoprecipitation with irrelevant mouse Ig and protein G-
agarose (mIgG).
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derstanding monogenic -cell disorders and, more recently,
genomewide association studies have identified several common
variants thought to be primarily associated with -cell dysfunc-
tion, progress in understanding the genetic basis of insulin
resistance remains slow (12, 13). This probably reflects the
complexity of the insulin signaling cascade, the fact that insulin
sensitivity is determined by insulin action in several different
tissues and the number of factors, such as body weight, diet,
physical activity, puberty, and old age, which modify insulin
sensitivity. All previously described monogenic disorders in the
insulin signaling cascade in humans result from proximal defects
in the pathway, the vast majority being the result of mutations in
the insulin receptor (14). We have also reported 1 kindred with
autosomal dominant fasting and postprandial hyperinsulinemia
because of a heterozygous AKT2 mutation (15). Although we
and others have screened several genes (including GLUT4)
implicated in GLUT4 trafficking, the premature stop TBC1D4
variant (R363X) is the first mutation that significantly impairs
GLUT4 translocation.
The prematurely truncated TBC1D4 protein, which lacks the
Rab-GTPase domain and AKT phosphorylation sites, slightly
increases basal GLUT4 cell membrane levels. Expression of the
truncation mutant may displace some wild-type TBC1D4 from
the GLUT4 vesicles. Since the truncated protein lacks a GAP
domain, one might expect an increase in GTP-bound Rab
substrate proteins and consequently increased basal GLUT4
translocation. The inhibition of GLUT4 at the cell surface in the
insulin-stimulated state caused by overexpression of the R363X
and 383Tr is qualitatively consistent with the concept that the
R363X mutation inhibits GLUT4 translocation in humans.
However, it should be noted that quantitatively the degree of
inhibition would be expected to be small when the amount of the
truncated protein is expressed at about the same level as the
wild-type protein, as would be the case in the human heterozy-
gote, since 30-fold overexpression in 3T3L1 adipocytes de-
creased the amount of GLUT4 at the cell surface by 34%. Thus,
it remains possible that some unknown role of TBC1D4 in other
tissues contributes to the human phenotype. TBC1D4 mRNA is
widely expressed in human tissues with highest expression in
skeletal muscle and white adipose tissue (16, 17). Exactly how the
truncated mutant inhibits insulin-stimulated GLUT4 transloca-
tion remains unclear. One possibility is that association of the
truncated mutant with wild-type TBC1D4 reduces the suppres-
sion of its GAP activity that normally occurs when TBC1D4 is
phosphorylated in response to insulin. As a result, insulin
stimulation leads to a smaller increase in GTP-bound Rabs and
thus some inhibition of GLUT4 translocation. Alternatively, it is
possible that phosphorylated full-length TBC1D4 also has a
positive role in GLUT4 translocation. This notion is consistent
with observations made in TBC1D4 knockdown experiments;
knocking down TBC1D4 in 3T3L1 adipocytes caused a 3-fold
increase in GLUT4 at the cell surface in the basal state and a
25% reduction in cell surface GLUT4 levels in the insulin-
treated state (8).
We have found that TBC1D4 dimerises with itself (Fig. 3D).
The fact that the truncated protein can associate with full-length
TBC1D4 offers a potential mechanism whereby relatively low-
level expression of the variant might impair GLUT4 transloca-
tion. This is important for 2 reasons: first, the variant is het-
erozygous and second, at least in the 3T3L1 adipocytes, we
observed considerable readthrough of the premature stop
codon. Previous studies suggest that TGA stop codons, which is
what the patients in this kindred have, appear to be the leakiest
of all stop codons (18, 19), but whether or not this is occurring
in vivo and to what extent it might be occurring is difficult to
quantify accurately. Nevertheless, immunoblots of lysates from
the proband’s transformed lymphocytes suggest that total
TBC1D4 expression levels are reduced and that the truncated
TBC1D4 protein is expressed. Alternatively, given the increased
basal GLUT4 levels with reduced insulin-induced GLUT4 trans-
location seen in TBC1D4 knockdown 3T3L1 adipocytes (8), it is
also plausible that the phenotype may simply be explained by
reduced TBC1D4 expression in vivo.
Two aspects of the human R363X phenotype were particularly
striking: first, the proband presented with a very modestly
elevated fasting insulin level of 101 pmol/L, but a massively
elevated postglucose insulin peak of 6,237 pmol/L. We hypoth-
esize that this selective preservation of fasting glucose and
insulin levels with marked postprandial hyperinsulinaemia might
reflect (i) preserved insulin action in the liver being primarily
Table 1. Clinical and biochemical characteristics of the proband and her mother
Proband Reference ranges, mean (95% CI)* Mother Reference ranges, mean (95% CI)*
Age (years) 11 41
Sex F F
BMI (kg/m2) 27 37
BMI SDS 2.7 3.1
Basal glucose (mg/dL) 97.3 84.1 (83.2; 85.0) 81.1 90.8 (86.7; 95.0)
120 min glucose (mg/dL) 158.6 102.1 (100.1; 104.2) 137.0 103.6 (95.0; 112.3)
Basal insulin (pM) 101 94 (85; 103) 115 80 (70; 92)
120 min insulin (pM) 6237 460 (413; 508) 1720 367 (283; 452)
120 min/basal insulin ratio 62 4.8 (4.7;4.8)† 15 4.7 (3.9; 5.4)†
HbA1C 5.3%
Triglyceride (mg/dL) 88.5 115 177
Cholesterol (mg/dL) 146.7 169.9 193
HDL Cholesterol (mg/dL) 61.8 46.3 38.6
To convert the values for glucose into millimoles per liter multiply by 0.0555. To convert the values for insulin to microinternational units per milliliter divide
by 6.945. To convert the values for triglycerides to millimoles per liter multiply by 0.0113. To convert the values for cholesterol and HDL to millimoles per liter
multiply by 0.0259.
*Age-, gender-, and BMI-matched control data for the proband were derived from oral glucose tolerance tests performed in 215 nondiabetic Caucasian girls (23)
[mean and 95% CI for: age 11.46 years (11.13; 11.79); BMI, 29.1 kg/m2 (28.3; 29.9)]. Gender- and BMI-matched data for the mother were derived from 31
nondiabetic Caucasian adult women participating in the Isle of Ely study (24) (BMI range 35–40 kg/m2).
†In control subjects, peak insulin values usually occur at 30 or 60 min. Definitive peak insulin data were not available as plasma insulin was only measured at 30
and 120 min after the oral glucose load in the adolescent controls and at 30, 60, and 120 min in the adult controls; however, in these control samples, the mean
ratios for 30 min and 120 min to basal insulin concentrations were 9 and 5, respectively, in the gender- and BMI-matched adolescents; and the mean ratios for
60 and 120 min to basal insulin concentrations were 7 and 5, respectively, in gender- and BMI-matched adults.
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responsible for maintaining fasting glucose levels, (ii) increased
basal (fasting) membrane GLUT4 levels, and (iii) impaired
insulin-stimulated GLUT4 translocation. In vivo, the tendency
to increase basal GLUT4 membrane expression does not appear
to be sufficient to cause hypoglycemia as none of the carriers
manifest this problem, but supraphysiological doses of insulin are
required to compensate for the postprandial defect in insulin-
stimulated GLUT4 translocation. Within a cohort of over 200
probands with severe insulin resistance, we have only identified
3 other probands with similarly disproportionate postglucose
hyperinsulinemia. We have yet to identify causative genetic
variants in these patients.
Second, the phenotype observed in this kindred appears to be
very subtle in lean carriers (in keeping with the apparently subtle
in vitro effects of the truncated mutant) but particularly sensitive
to secondary modifiers such as puberty and obesity. Puberty is
a well-recognized but ill-understood cause of insulin resistance.
Intriguingly, it also appears to cause predominantly peripheral as
opposed to hepatic insulin resistance (20). Although the kindred
described herein is small, the proband’s phenotype was most
apparent during puberty and improved significantly following
the completion of puberty and weight loss. Following puberty
and significant weight loss the proband’s acanthosis nigricans
resolved and her insulin levels fell considerably although she was
still overweight and had a high peak-to-basal insulin ratio. Her
aunt normalized her fasting and postglucose insulin levels after
reducing her BMI to 24 kg/m2, whereas her mother, who
remained obese, maintained elevated peak insulin levels. The
fact that GLUT4 levels are known to be specifically reduced in
adipose tissue in obese states might explain the predisposition of
this phenotype to be exacerbated by obesity (21).
A limitation of this study is the absence of direct in vivo
measurements of GLUT4 expression and of glucose transport in
adipose tissue and skeletal muscle. Family members declined our
invitation to undergo hyperinsulinemic euglycemic clamps
which, whilst still not providing direct measurements of in vivo
glucose transport, might at least have indicated impaired pe-
ripheral glucose disposal.
In summary, we have described a family in which the proband,
who presented with acanthosis nigricans and extreme posting-
estive hyperinsulinemia, was found to have inherited a heterozy-
gous premature stop mutation in TBC1D4. In vitro, the mutant
protein binds wild-type TBC1D4 and inhibits GLUT4 translo-
cation. Thus, it is plausible to suggest that this family may
represent the first inherited disorder of GLUT4 translocation in
humans. Of clinical importance is the fact that reliance on
biochemical assessments of insulin resistance that incorporate
only fasting insulin would not have suggested a diagnosis of a
state of severe insulin resistance in the proband, when she
presented with acanthosis nigricans, and could have led to
subsequent misdirected investigation. This family demonstrates
that clinical syndromes of severe isolated postprandial hyperin-
sulinemia, sufficient to produce the classical dermatological
marker of severe insulin resistance, exist in the human popula-
tion and that their recognition requires measurement of circu-
lating insulin levels in the postprandial and fasting states.
Methods
Genetic Studies. Each participant, or a parent in the case of children under 16
years, provided written informed consent; minors provided oral consent. All
clinical studies were conducted in accordance with the principles of the
Declaration of Helsinki and were approved by the National Health Service
Research Ethics Committee.
Genomic DNA was isolated from leukocytes derived from whole blood from
156 probands with severe insulin resistance and the coding regions and splice
junctions of TBC1D4 (AS160) were amplified by PCR and sequenced. EBV-
transformed lymphocytes were lysed in 50 mmol/L Hepes (pH 7.4), 150 mmol/L
NaCl, 10 mmol/L ethylenediamine tetraacetate, 0.5 mmol/L phenylmethylsul-
fonylfluoride, 2.5 mmol/L benzamidine, 1 g/mL leupeptin, antipain, pepsta-
tin, and 1% Triton X-100. Protein concentration was determined using the
Bradford dye-binding procedure (Bio-Rad Laboratories). Cell lysates were
subjected to 8% reducing SDS/PAGE, proteins were transferred to Immo-
bilon-P polyvinylidene difluoride membranes (Millipore), and membranes
were probed with a rabbit polyclonal antibody raised against the C terminus
of TBC1D4 and a horseradish peroxidase-conjugated secondary antibody
(Abcam). Antibody binding was detected by enhanced chemiluminescence
(Amersham ECL Western blotting system, GE Healthcare).
To demonstrate expression of the truncated protein, we obtained a cus-
tom-made affinity-purified rabbit antibody raised against the N terminus of
TBC1D4 (21st Century Biochemicals). EBVL lysates were immunoprecipitated
with this N-terminal TBC1D4 antibody using the Exactacruz F kit from Santa
Cruz Biotechnology (catalog no. sc-45043) as per manufacturer’s instructions.
Protein A agarose beads (Sigma, catalog no. P3476–5ML) were used to bind
the N-terminal anti-TBC1D4 antibody. Bead-antibody-protein complexes
were washed 4 times in lysis buffer and then finally in PBS. The immunopre-
cipitated protein was eluted in 50 L of 2 nonreducing electrophoresis
buffer by gentle pipetting at room temperature. Nonreducing buffer was
used because the mobility of the reduced truncated protein is approximately
the same as that of the antibody heavy chain. The supernatant was run on an
A
B
Fig. 4. Phenotypic characterization of the R363X TBC1D4 kindred. (A)
Plasma insulin levels (pmol/L) before (0 min) and after (30, 60, and 120 min) a
75-g oral glucose challenge. Black squares and error bars represent mean and
95% CI for plasma insulin levels during oral glucose tolerance tests performed
in 215 nondiabetic Caucasian girls (23) (control; mean and 95% CI for: age,
11.46 years (11.13; 11.79); BMI, 29.1 kg/m2 (28.3; 29.9). Red diamonds denote
data derived from the proband (proband) at age 11 years and blue circles, data
from a 13-year-old lean female (IR) with type A insulin resistance because of
a dominant negative mutation in the insulin receptor (INSR A1135E), which
causes severe hepatic and peripheral insulin resistance. (B) Proband’s (Ii) family
pedigree. The squares represent male family members and the circles female
family members; solid symbols denote family members with acanthosis nig-
ricans. Below each symbol, age (years) is given, followed by the BMI (kg/m2),
the BMI standard deviation score (SDS), the peak-to-basal insulin ratio, and
the genotype, with N denoting the normal (wild-type) allele and M the mutant
allele. IFG, impaired fasting glucose; IGT, impaired glucose tolerance.
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8% SDS gel and immunoblotted with the N-terminal TBC1D4 antibody as
described above except that a HRP-conjugated secondary antibody from the
Exactacruz kit was used for detection. The truncated R363X protein is detected
at just above the 50-kDa marker when dissolved in reduced electrophoresis
buffer. To determine its molecular weight in a nonreducing buffer, protein
lysates from 3T3L1 adipocytes overexpressing a myc-tagged 363Tr were dis-
solved in 2 nonreducing buffer and immunoblotted with an antibody raised
against the myc epitope. This confirmed that the truncated protein was
detectable just above the 75-kD marker (Fig. S1).
Cellular Studies of Mutant TBC1D4 Function. Human wild-type TBC1D4 (AS160)
in the P3XFLAG CMV10 vector (6) was used to generate a Flag-tagged mutant
construct (R363X) using the QuikChangeTM site-directed mutagenesis kit
(Stratagene) according to the manufacturer’s protocols. To evaluate the
biological effects of the truncated mutant, a second construct was created in
this vector with no coding DNA beyond the stop codon identified in the
proband (designated 363Tr). All constructs were fully sequenced.
The relative amount of GLUT4 at the cell surface in 3T3L1 adipocytes was
assayed by transfecting cells through electroporation with a plasmid for
expression of HA-GLUT4-GFP and measuring the HA-GLUT4-GFP at the cell
surface by quantitative single-cell immunofluorescence, as previously de-
scribed (7). In this method, HA-GLUT4-GFP at the cell surface is labeled with
anti-HA and Cy3-conjugated secondary antibody; the fluorescence intensities
for Cy3 and GFP in individual cells are quantitated, and the relative amount of
HA-GLUT4-GFP at the cell surface is expressed as the ratio of Cy3 to GFP, to
correct for different levels of expression of the HA-GLUT4-GFP protein.
The association of TBC1D4 with itself and with the 363Tr form was exam-
ined by cotransfecting human embryonic kidney 293E cells with plasmids for
expression of N-terminal T7-tagged human TBC1D4 and either N-terminal
Flag-tagged TBC1D4 or the 363Tr with Lipofectamine 2000. The cells were
treated with insulin (1M for 10 min) or left unstimulated, then lysed in 40 mM
Hepes, 150 mM NaCl, pH 7.4 containing 1.5% nonionic detergent octaethyl-
eneglycol dodecyl ether and protease and phosphatase inhibitors. The lysate
was cleared by centrifugation at 12,000 g for 15 min and the portions of the
supernatant were immunoprecipitated with anti-Flag agarose or irrelevant
mouse Ig and protein G-agarose. SDS samples of the immunoprecipitates were
immunoblotted for the T7 and Flag epitopes.
Glucose Tolerance Tests and Biochemical Assays. Whole body insulin sensitivity
was assessed with a 2-hour, 75-g oral glucose tolerance test. After insertion of
an antecubital i.v. line, blood samples were collected at30, 0, 10, 30, 60, 90,
and 120 min for determination of plasma glucose, insulin, c-peptide, and free
fatty acids. Insulin, leptin, and adiponectin were measured using customized
autoDELFIA immunoassays as previously described (22).
Statistical Analysis. GLUT4 translocation data are expressed as means  SE.
Differences between vectors were compared with use of the unpaired Stu-
dent’s t test. All reported P values are from 2-sided tests, and P values of less
than 0.05 were considered to indicate statistical significance.
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